Induction and Postremission Treatment Results
| Induction | ||
| CR | 186 (77%) | |
| Failed induction | ||
| No response | 40 (16%) | |
| Died in induction | 17 (7%) | |
| Total | 243 | |
| Postremission intensification |
| Induction | ||
| CR | 186 (77%) | |
| Failed induction | ||
| No response | 40 (16%) | |
| Died in induction | 17 (7%) | |
| Total | 243 | |
| Postremission intensification |
| Course 1 | |||
| Course 2 | |||
| Course 3 | |||
| No. eligible | 186 | 170 | 153 |
| Started course | 176 | 157 | 127 |
| Did not start | |||
| Treatment discontinued | 6 | 1 | 4 |
| Withdrew | 2 | 10 | 15 |
| Relapse | 2 | 2 | 7 |
| Completed course | 170 | 153 | 112 |
| Did not finish | |||
| Treatment discontinued | 3 | 1 | 0 |
| Withdrew | 0 | 0 | 0 |
| Relapsed | 2 | 2 | 5 |
| Died | 1 | 1 | 6 |
| Lost to follow-up | 0 | 0 | 1* |
| Other treatment | 0 | 0 | 3* |
| Course 1 | |||
| Course 2 | |||
| Course 3 | |||
| No. eligible | 186 | 170 | 153 |
| Started course | 176 | 157 | 127 |
| Did not start | |||
| Treatment discontinued | 6 | 1 | 4 |
| Withdrew | 2 | 10 | 15 |
| Relapse | 2 | 2 | 7 |
| Completed course | 170 | 153 | 112 |
| Did not finish | |||
| Treatment discontinued | 3 | 1 | 0 |
| Withdrew | 0 | 0 | 0 |
| Relapsed | 2 | 2 | 5 |
| Died | 1 | 1 | 6 |
| Lost to follow-up | 0 | 0 | 1* |
| Other treatment | 0 | 0 | 3* |
These four patients are not evaluable for recovery from myelosuppression. One patient in group 1 and two in group 2 received G-CSF during their course.